Biomarkers to Assess Acute Kidney Injury Risk During Heat Strain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Riana R Pryor, PhD
- Phone Number: 7163489306
- Email: rpryor@buffalo.edu
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14214
- Recruiting
- Center for Research and Education in Special Environments
-
Contact:
- Jocelyn Stooks, MPH
- Phone Number: 716-829-5455
- Email: jstooks@buffalo.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy individuals (18-39 years old)
- Regularly completes aerobic exercise at least 60 min per week
Exclusion Criteria:
- History of cardiovascular, metabolic, respiratory, neural, or renal disease
- Hypertensive or tachycardic during the screening visit (systolic blood pressure > 139 mmHg, diastolic blood pressure > 89 mmHg, heart rate > 100 bpm)
- Current tobacco or nicotine use or previous regular use within the past 2 years
- Current or previous musculoskeletal injury limiting physical activity
- Taking medications with known thermoregulatory or cardiovascular effects (e.g., aspirin, beta blockers, diuretics, psychotropics, etc.)
- A positive pregnancy test at any point during the study or currently breastfeeding
- Study physician discretion based on any other medical condition or medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Work Heat Stress
Each participant will complete three consecutive days of heavy intensity aerobic work in a hot environment.
|
Participants will complete 4 hours of walking and cycling to a work:rest ratio of 3:1.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
[TIMP-2 x IGFBP-7] concentration
Time Frame: Minute 0
|
The product of [Tissue inhibitor of metalloproteinase 2 (TIMP-2) and Insulin-like growth factor binding protein 7 (IGFBP7)] is a biomarker that has the potential for prediction of acute kidney injury.
|
Minute 0
|
|
[TIMP-2 x IGFBP-7] concentration
Time Frame: Hour 4
|
The product of [Tissue inhibitor of metalloproteinase 2 (TIMP-2) and Insulin-like growth factor binding protein 7 (IGFBP7)] is a biomarker that has the potential for prediction of acute kidney injury.
|
Hour 4
|
|
[TIMP-2 x IGFBP-7] concentration
Time Frame: Hour 5
|
The product of [Tissue inhibitor of metalloproteinase 2 (TIMP-2) and Insulin-like growth factor binding protein 7 (IGFBP7)] is a biomarker that has the potential for prediction of acute kidney injury.
|
Hour 5
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NGAL concentration
Time Frame: Minute 0
|
Neutrophil gelatinase-associated lipocalin (NGAL) measures kidney injury.
|
Minute 0
|
|
NGAL concentration
Time Frame: Hour 4
|
Neutrophil gelatinase-associated lipocalin (NGAL) measures kidney injury.
|
Hour 4
|
|
NGAL concentration
Time Frame: Hour 5
|
Neutrophil gelatinase-associated lipocalin (NGAL) measures kidney injury.
|
Hour 5
|
|
Serum creatinine concentration
Time Frame: Minute 0
|
Serum creatinine concentration is a measure of kidney function.
|
Minute 0
|
|
Serum creatinine concentration
Time Frame: Hour 4
|
Serum creatinine concentration is a measure of kidney function.
|
Hour 4
|
|
Serum creatinine concentration
Time Frame: Hour 5
|
Serum creatinine concentration is a measure of kidney function.
|
Hour 5
|
|
Urine creatinine concentration
Time Frame: Minute 0
|
Urine creatinine concentration is a measure of kidney function.
|
Minute 0
|
|
Urine creatinine concentration
Time Frame: Hour 4
|
Urine creatinine concentration is a measure of kidney function.
|
Hour 4
|
|
Urine creatinine concentration
Time Frame: Hour 5
|
Urine creatinine concentration is a measure of kidney function.
|
Hour 5
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00005847-Pilot
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.